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E-mail address: ljiljana.zmak@hzjz.hr (L.Mycobacterium tuberculosis remains a major global health problem and is currently killing 1.5
million people every year. One of the most important steps in tuberculosis control is the
rapid and accurate laboratory diagnosis. The Xpert MTB/RIF assay is a novel molecular,
easy-to-use assay, which can lead to tuberculosis identification in less than 2 h. In this
study, the Xpert MTB/RIF assay performance for rapid diagnosis of tuberculosis was evalu-
ated in comparison with conventional culture methods; 361 pulmonary and extrapulmo-
nary patient samples were collected between October 2010 and October 2012 and were
analyzed at the National Reference laboratory for Mycobacteria, Zagreb, Croatia. For pul-
monary samples the sensitivity and specificity were 86% and 100%, while for extrapulmo-
nary samples the sensitivity and specificity were 75% and 99%, respectively. It was
concluded that Xpert MTB/RIF assay has high sensitivity and specificity for both pulmonary
and extrapulmonary specimens.
 2013 Asian-African Society for Mycobacteriology. Published by Elsevier Ltd. All rights
reserved.Introduction methods [3]. The Xpert MTB/RIF is a novel automated molec-Mycobacterium tuberculosis remains a major global health prob-
lem and is currently killing three persons every minute.
Although the tuberculosis (TB) death rate dropped more than
40% between 1990 and 2011, more has to be done in order to
reach the Stop TB partnership goal of zero tuberculosis deaths
in this lifetime [1,2]. While waiting for a new and efficient TB
vaccine to come in use, other key points in TB control must be
addressed. One of the most significant steps in TB control is
the fast and accurate disease diagnosis. Although culture is
the gold standard for final disease determination, it is slow
and actually out of reach in low-income countries. In the last
couple of years there has been a major breakthrough in the
diagnosis of TB owing to the discovery of fast molecular-African Society for Myco
nt for TB Diagnosis, Croa
85 1 4863288.
Zmak).ular assay recently endorsed by the World Health Organiza-
tion for the early diagnosis of both M. tuberculosis infection
and rifampin resistance [4]. The sample processing, nucleic
acid extraction, amplification and detection of rifampicine
resistance are performed in a single cartridge within 2 h.
The assay velocity in detecting both M. tuberculosis and rif-
ampicine resistance enable us to stop the spread of disease
and give appropriate treatment considerably faster compared
with conventional methods.
The researchers from the Cochrane Infectious Diseases
Group, McGill University, and the Foundation for Innovative
New Diagnostics (FIND) have recently analyzed data from 18
studies involving a total of 7816 people, in order to review the
diagnostic accuracy of Xpert MTB/RIF assay [5]. The reviewbacteriology. Published by Elsevier Ltd. All rights reserved.
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ificitywhenused as an initial diagnostic test for TB and rifamp-
icine resistancedetection inpatients suspectedofhavingTB [5].
The Xpert MTB/RIF assay has been in use at the National
Reference Laboratory (NRL) for Tuberculosis of the Croatian
National Institute of Public Health (CNIPH) since October
2010.With 680 newly diagnosed patients in 2011, the incidence
of tuberculosis in Croatia is 15/100,000 population [6]. The pro-
portion of resistant strains amongnew isolates is 3%,while the
proportion of multidrug-resistant (MDR) tuberculosis is below
1% [6]. Although the NRL performs a third-level laboratory ser-
vice for the whole country, it is actually also involved in first-
and second-level laboratory work for several counties.
The aim of the present study was to determine the perfor-
mance of the Xpert MTB/RIF assay for the rapid diagnosis of
tuberculosis and rifampicine resistance from pulmonary
and extrapulmonary patient samples. The results obtained
with the Xpert MTB/RIF assay were compared with conven-
tional culture methods.
Material and methods
Clinical samples
All samples included in the study were collected between
October 2010 and October 2012 at the National Reference lab-
oratory for Mycobacteria, Zagreb, Croatia. Out of 361 total
clinical samples collected, 120 were pulmonary and 241 were
extrapulmonary; 309 were suspected tuberculosis patients.
The 120 pulmonary samples included 51 bronchial aspirates,
24 bronchoalveolar lavages, 42 sputum and 3 gastric lavages.
The 241 extrapulmonary samples included 50 urine, 46 cere-
brospinal fluid (CSF), 58 tissue samples, 10 ascitic fluid, 11
blood samples, 17 pericardial fluid, 42 pleural fluid, 4 skin
swabs and 3 stool specimens.
Non-sterile specimens were processed by the standard N-
acetyl-L-cysteine and sodium hydroxide (NALC/NaOH) meth-
od and smearswere prepared by the auramine acid-fast stain-
ing method. After decontamination, specimens were
inoculated to both solid and liquid mediums.
MGIT 960
MGIT tubes were inoculated with 0.5 ml of the processed
specimen. The tubes were incubated in the MGIT 960 instru-
ment at 37 C for up to 6 weeks. For tubes identified as posi-
tive, a smear of a sample from the tube was prepared for
examination for acid-fast bacilli (AFB) by Ziehl–Neelsen stain.
Further differentiation of mycobacteria was performed with
molecular methods and biochemical tests (CM/AS/MTBC as-
say, Hain Lifescience, GmbH, Nehren, Germany).
Solid media
For each specimen, one Lowenstein–Jensen (LJ) slant and one
Stonebrink slant were inoculated with 0.1 ml suspension and
incubated at 37 C. Bacterial colonies were investigated by
AFB smear and were further investigated by molecular meth-
ods and biochemical tests.DST
Drug susceptibility testing (DST) for rifampicine was per-
formed for all culture-positive samples with the proportion
method on LJ solid medium as previously described (standard
critical concentration of 40 lg/ml).
Xpert MTB/RIF procedure
Xpert MTB/RIF assay was performed and results were inter-
preted according to the manufacturer’s instructions [7].
Briefly, sample reagent was added in a 3:1 ratio to 0.5 ml of
decontaminated specimen. The closed tube was manually
agitated twice during a 15-min incubation period at room
temperature before 2 ml of the reagent-sample mixture was
transferred to the Xpert test cartridge. Cartridges were in-
serted into the Xpert device, and the automatically generated
results were read after 90 min.
Results
Patients and conventional culture
A total of 361 clinical samples originating from 309 suspected
tuberculosis patients were analyzed, of which 120 were pul-
monary and 241 were extrapulmonary.
Of the 120 pulmonary samples, 7 were culture-positive for
M. tuberculosis and 2 were culture-positive for Mycobacterium
intracellulare. The rest of the 111 samples were culture-nega-
tive (Table 1).
Of the 241 extrapulmonary samples, 12 were culture-posi-
tive forM. tuberculosis complex (MTC), while 229 were culture-
negative. From the 12 culture-positive samples, 9 were identi-
fied asM. tuberculosis, while 3 were identified asMycobacterium
bovis (Table 1).
Xpert MTB/RIF assay performance
Of the 7 culture-positive pulmonary samples, 6 were also po-
sitive withXpert MTB/RIF analysis (3 sputum, 2 bronchial aspi-
rates and 1 bronchoalveolar lavage fluid). Three of the 7
culture-positive samples were also smear-positive (2 sputum
and 1 bronchial aspirate), and all were identified asM. tubercu-
losis with Xpert MTB/RIF assay.
Of the 12 culture-positive extrapulmonary samples, 9 were
also positive with Xpert MTB/RIF analysis (5 tissue samples, 2
skin swabs, 1 peritoneal fluid and 1 CSF). One tissue sample
and both skin samples, which were found culture-positive
and Xpert MTB/RIF positive, were identified as M. bovis. All
the culture-positive samples, except skin swabs, were
smear-negative. There were also two CSF samples identified
positive with Xpert MTB/RIF assay and negative with conven-
tional culture methods.
According to the conventional culture results, the sensitiv-
ity of Xpert MTB/RIF analysis for all samples was 79%, and the
specificity was 99% (Table 2).
For pulmonary samples, the sensitivity, specificity, positive
predictive value (PPV) and negative predictive value (NPV)
were 86%, 100%, 100% and 99%, respectively. The sensitivities
Table 1 – The specimens analyzed and smear and culture results.
Specimen type Smear + Smear  Culture (MTC)+ Culture (MTC) M. intracellulare
Pulmonary (n = 120)
Bronchial aspirates (n = 51) 1 50 2 48 1
Sputum (n = 42) 2 40 4 37 1
BAL (n = 24) 0 24 1 23 0
Gastric lavage (n = 3) 0 3 0 3 0
Extrapulmonary (n = 241)
Urine (n = 50) nda nda 0 50 0
CSL (n = 46) 0 46 1 45 0
Pleural fluid (n = 42) 0 42 1 41 0
Pericardial fluid (n = 17) 0 17 0 17 0
Blood (n = 11) 0 11 0 17 0
Tissue (n = 58) 0 58 5 (1M.bovis) 53 0
Ascitic fluid (n = 10) 0 10 3 7 0
Skin swab (n = 4) 2 2 2 (2M.bovis) 2 0
Stool (n = 3) nda nda 0 3 0
a Not done.
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specimens, respectively.
For extrapulmonary samples, the sensitivity, specificity,
PPV and NPV were 75%, 99%, 75% and 99%, respectively. The
sensitivity for smear-positive samples was 100%, while for
smear-negative specimens it was 70%.
The specificity and NPV for smear-positive pulmonary and
extrapulmonary samples was not calculable, as there were no
negative test results.
Susceptibility testing was performed for all culture-posi-
tive samples and all isolates were found to be susceptible to
rifampicine with both conventional proportion method and
XpertMTB/RIF testing. Moreover, the isolates tested with the
conventional proportion method were found to be susceptible
to all first-line antituberculotic drugs.
Discussion
One of the most important steps in tuberculosis control is the
rapid and accurate laboratory diagnosis which leads to faster
treatment and faster epidemiological control. In this study,
the aim was to investigate the performance of Xpert MTB/
RIF assay, a rapid molecular test, in the routine laboratory
work at the National Reference Laboratory for Mycobacteria,
Zagreb, Croatia. Previous studies have reported high sensitiv-Table 2 – Sensitivity, specificity, and positive and negative pred
method as gold standard.
Specimen type Sensitivity (%)
All samples 79
Pulmonary (all) 86
Smear + 100
Smear  75
Extrapulmonary (all) 75
Smear + 100
Smear  70
a Not calculable.ity and specificity for Xpert MTB/RIF assay, especially in smear
positive samples. In the present investigation, high sensitivity
and specificity for smear-positive, both pulmonary and extra-
pulmonary specimens, was also detected. Lower sensitivity
was observed in smear-negative pulmonary samples (75%),
and especially in smear-negative extrapulmonary samples
(70%). However, considering that the Xpert MTB/RIF test is fin-
ished in 3 h, its sensitivity is considerably higher than those
of smear microscopy which in was 43% in this study in com-
parison with Xpert MTB/RIF which was 79%. Moreover, it
would be interesting to asses the usefulness of this method
on extrapulmonary samples where the smear is not carried
out. In the routine analysis of urine or stool specimens for
M. tuberculosis infection, one depends on culture results,
which are time-consuming and actually out of reach for many
field laboratories. Unfortunately, there was no culture-posi-
tive result from urine or stool samples in this study, but pre-
vious studies described high specificity of Xpert MTB/RIF in
detecting M. tuberculosis in urine and stool specimens [8].
When analyzing pulmonary samples, Xpert MTB/RIF did
not detect M. tuberculosis DNA in only 1 sputum sample out
of 7 culture-positive samples. However, when looking at
extrapulmonary samples, XpertMTB/RIF missed 3 M. tubercu-
losis infections, including 1 pleural fluid sample and 2 ascitic
fluid samples. Low detection of M. tuberculosis in ascitic fluidictive values of the GeneXpert MTB/RIF assay with culture
Specificity (%) PPV(%) NPV(%)
99 83 99
100 100 99
nca 100 nca
100 100 97
99 75 99
nca 100 nca
99 70 99
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that Xpert MTB/RIF missed 3 out of 4 positive ascitic fluid
samples [9].
In this study, two CSF samples and one tissue sample
were identified as positive using Xpert MTB/RIF assay and
negative using conventional culture methods. One patient
with a culture-negative/Xpert positive result from CSF was
subsequently positive in further sample analyses on conven-
tional culture and was diagnosed as tuberculosis infection.
The other two culture-negative/Xpert positive patients were
diagnosed as active tuberculosis and clinically recovered
after antituberculotic treatment. These results indicate the
possible value of Xpert MTB/RIF assay in detecting M. tubercu-
losis in samples of small bacillary load, especially CSF
samples.
Drug susceptibility testing was performed for all culture-
positive samples and all isolates were found to be susceptible
to rifampicinewith both conventional proportionmethod and
Xpert MTB/RIF testing.Conclusion
From this investigation, it can be concluded that Xpert
MTB/RIF assay has high sensitivity and specificity for both
pulmonary and extrapulmonary specimens. Moreover, it
was found that this molecular assay is a very fast and use-
ful tool for the rapid diagnosis of tuberculosis infection,
especially in some extrapulmonary samples with low bacil-
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